Pharmacists Must Lead Again:
Making Clozapine TDM Standard Practice
Join this AAPP webinar initially recorded on July 15, 2026.
Description:
Pharmacists have led therapeutic drug monitoring (TDM) initiatives in antimicrobial stewardship, transplant medicine, and oncology for decades. So why isn’t TDM yet standard practice for clozapine, the most effective treatment for treatment-resistant schizophrenia?
Despite significant variability in clozapine metabolism and strong guideline support for therapeutic drug monitoring, clozapine levels remain underutilized in routine practice. With rapid clozapine testing now available, pharmacists have an opportunity to lead the next evolution in personalized psychiatric care.
Join Megan Ehret, PharmD, MS, BCPP, FAAPP, and Jordan Reese, PharmD, BCPP, as they explore how pharmacists can drive the adoption of real-time clozapine TDM. Dr. Reese will share his experience leading the implementation of a rapid clozapine monitoring program at Colorado Mental Health Hospital.
Whether you are considering implementing a clozapine TDM program or looking to expand its clinical impact, this webinar will provide practical strategies to help pharmacists lead practice change and advance personalized clozapine care.
Presenting Faculty:
Megan Ehret, PharmD, MS, BCPP, FAAPP
- Professor
- Co-Director of Mental Health Program
- Vice-Chair of Academic Affairs
- Department of Practice, Sciences, and Health Outcomes Research
- University of Maryland School of Pharmacy
Jordan Reese, PharmD, BCPP
- Clinical Pharmacy Specialist
- Colorado Mental Health Hospital in Pueblo (CMHHIP)
Additional Resources:
For additional handouts, questions, or inquiries, please contact hello@saladax.com or enter your email below!
